Profilo
Theresa Mansi is associated with NexEos Diagnostics, Inc. and NexEos Bio, Inc. as the Chief Executive Officer and Director, and Chief Executive Officer respectively.
Posizioni attive di Theresa Mansi
| Società | Posizione | Inizio |
|---|---|---|
NexEos Diagnostics, Inc.
 NexEos Diagnostics, Inc. Medical/Nursing ServicesHealth Services NexEos Diagnostics, Inc. operates as a medical diagnostics company focuses on disorders related to white blood cells. The company is headquartered in Wayne, PA. | Amministratore Delegato | - |
NexEos Bio, Inc.
 NexEos Bio, Inc. Medical/Nursing ServicesHealth Services NexEos Bio is a medical diagnostics company that aims to improve the detection, diagnosis, treatment, and management of patients with chronic, eosinophil-related inflammatory diseases. The company is based in Wayne, PA. The company's lead program is a non-invasive imaging agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis (EoE). This program has the potential to improve patients' quality of life, more rapidly diagnose their disease, and may help delay disease progression. The company was founded by Gerald Gleich, and the CEO is Theresa Mansi. | Amministratore Delegato | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
NexEos Diagnostics, Inc.
NexEos Diagnostics, Inc. Medical/Nursing ServicesHealth Services NexEos Diagnostics, Inc. operates as a medical diagnostics company focuses on disorders related to white blood cells. The company is headquartered in Wayne, PA. | Health Services |
NexEos Bio, Inc.
NexEos Bio, Inc. Medical/Nursing ServicesHealth Services NexEos Bio is a medical diagnostics company that aims to improve the detection, diagnosis, treatment, and management of patients with chronic, eosinophil-related inflammatory diseases. The company is based in Wayne, PA. The company's lead program is a non-invasive imaging agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis (EoE). This program has the potential to improve patients' quality of life, more rapidly diagnose their disease, and may help delay disease progression. The company was founded by Gerald Gleich, and the CEO is Theresa Mansi. | Health Services |
- Borsa valori
- Insiders
- Theresa Mansi
